Shares plunged 18.7% on signs of deceleration and a cautious outlook that failed to convince investors the company can deliver durable growth despite management’s long-term ambitions.

• First quarter performance was described as "in line" with expectations but fell short of reflecting Certara’s potential, highlighting underlying growth concerns.
• CEO emphasized restructuring and operational rigor to drive long-term growth, signaling current execution challenges.
• The company highlighted strong regulatory foothold and scientific leadership, but these strengths alone have not translated into near-term market enthusiasm.
• Management flagged expansion into AI-driven drug discovery as a key growth driver, yet investors appear unconvinced by the timeline or impact.
• No specific financial metrics or margin commentary were provided to offset concerns, contributing to the negative market reaction.